Remove BioTech Remove Digital Health Remove Drug Development Remove Life Science
article thumbnail

Accelerator Life Science Partners Launches Biotechnology Startup Company in Singapore with $16M in Series A Commitments

Digital Health Global

Our mission is to accelerate the commercialization of breakthrough innovations like the AUTAC platform for health impact, and we welcome Automera and ALSP to Singapore’s growing life sciences translational community.”

article thumbnail

Koneksa Announces Expanded Partnership with SSI Strategy to Scale the Adoption of Digital Biomarkers in Clinical Trials

Digital Health Global

Koneksa’s digital biomarker solutions include an industry-leading platform that gives research sponsors and clinical sites the ability to seamlessly aggregate data in real-time from devices, ePROs, patient diaries, and clinical assessments to provide the full picture of an individual’s health.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Seamless Therapeutics Launches with $12.5M Seed Financing to Advance Transformative Gene Editing Platform Based on Programmable Precision Designer Recombinases

Digital Health Global

The seed round was co-led by Wellington Partners and Forbion and includes non-dilutive financing from BMBF GO-Bio, a prestigious German government initiative aimed at supporting the most innovative startups in the life sciences. Forbion invests in life sciences companies that are active in the (bio) pharmaceutical space.

article thumbnail

Medtech: BrainTale Gathers €4.5 Million to Accelerate the Development of Its Solution for Diagnosis, Monitoring and Prediction of Neurological Disorders

Digital Health Global

Founded in 2018 and supported from the outset by LallianSe, the life sciences integrator, BrainTale has developed and commercializes an accessible, reliable and clinically validated brain measurement digital platform solution for drug developers and physicians – neurologists, neuroradiologists and intensivists.

article thumbnail

Aviceda Therapeutics Announces Strategic Partnership with Queen’s University Belfast (QUB)

Digital Health Global

–(BUSINESS WIRE)– Aviceda Therapeutics , a clinical-stage biotech company focused on developing next-generation immuno-modulators to treat diseases such as cancer, today announced a strategic partnership with the Patrick G Johnston Centre for Cancer Research at Queen’s University Belfast (Queen’s). CAMBRIDGE, Mass.–(BUSINESS

article thumbnail

Let’s Save the Date and Make Patient Engagement Official in 2022

Society for Participatory Medicine

Healthcare stakeholders such as health systems, pharmaceutical companies, biotech and life sciences firms, and insurance companies serve patients as end users. Market forces drove acceleration in digital health, specifically telemedicine, which were sorely needed for several years. Did you enjoy this post?

BioTech 107
article thumbnail

Avilar Therapeutics Increases Financing to $75 Million to Advance Pipeline of Novel Extracellular Protein Degraders

Digital Health Global

Their expertise in company building, capital formation, and drug development will be a tremendous resource to Avilar as the innovation leader in the new field of extracellular protein degradation.” For more information, please visit www.avilar-tx.com and follow us on Twitter @Avilar_Tx and on LinkedIn.